ClinicalTrials.gg
Active, not recruitingNCT04923906Updated Nov 25, 2024

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

A Phase 3 interventional study of Aumolertinib and Placebo Aumolertinib in Non-small Cell Lung Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
624
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 29
624 · median 150
Started
2021
with 8 others
Phase 3
11 of 29
4 open now
Primary completion
2024-06
later than 4 of 17 live
Registered
15th of 29
by date
Lead sponsor
8 of 29
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 9 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 4 of the 17 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+).

Read the detailed description

HS-10296-306 is a randomized, open-label, multicenter, phase III study to assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+). Eligible patients are randomized to receive either Aumolertinib (110 mg orally, once daily) in combination with platinum-based chemotherapy (every 3 weeks for 4\~6 cycles) or Aumolertinib (110 mg orally, once daily) in a 1:1 ratio.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Concurrent Chemotherapy, Aumolertinib, EGFR-TKI, EGFRm+, Ex19Del, L858R, HS-10296, Stage IIIB-IV, Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Provision of before any study-specific procedures, sampling and analyses.

      1. Male or female, age at least 18 years. 3. confirmed locally advanced or NSCLC (included patients with stage IIIB, IIIC or IV disease who had after prior surgery or were newly diagnosed). Patients must be treatment-naïve for locally advanced or metastatic NSCLC. Prior and neo-adjuvant therapies are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.
      1. The tumor harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central testing using tumor tissue sample or blood sample.
      1. At least 1 lesion that has not previously been irradiated, and that can be accurately measured at Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm).
      1. An (ECOG) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
      1. Female patients should be using adequate measures and should not be breastfeeding at the screening period, during the study, and six months after the last dosing of study. Patient must have a negative pregnancy test prior to start of dosing if of or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at screening:
      2. defined as age more than 50 years and amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments.
      3. Women under 50 years old would be considered postmenopausal if they have been amenorrhea for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.
      4. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.

        1. Male patients should be willing to use barrier contraception (i.e., condoms).

Exclusion criteria

Exclusion Criteria:

    1. Treatment with any of the following:

      1. Prior treatment with an EGFR TKI.
      2. Major surgery (excluding placement of vascular access) within 4 weeks of randomization.
      3. Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of randomization.
      4. Spinal cord compression or unless asymptomatic, stable for at least 4 weeks, and not requiring for at least 2 weeks prior to start of study treatment.
      5. Medications that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.

        1. Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 2 at the time of starting study treatment.
        1. History of other , excluding full treated non-melanoma skin cancer, in-situ cancer, or other solid tumors that hadn't recurrent for > 5 years following the end of treatment.
        1. Inadequate bone marrow reserve or organ function. 5. Any of the following cardiac criteria:

      <!-- -->

      1. Mean resting interval (QTc) > 470 ms obtained from 3 (ECGs), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
      2. Any abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms).
      3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
      4. (LVEF) \< 50%. 6. Any evidence of severe or uncontrolled systemic diseases (including uncontrolled hypertension and active bleeding diatheses) or active infection. Screening for chronic conditions is not required.

        1. nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of Aumolertinib.
        1. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
        1. Women who are breastfeeding or have a positive urine or serum pregnancy test at the Screening Visit.
        1. History of to any active or inactive ingredient of study drugs (pemetrexed, cisplatin, carboplatin, Aumolertinib) or to drugs with a similar chemical structure or class to Aumolertinib.
        1. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
        1. Any severe and uncontrolled ocular disease that may, in the ophthalmologist's opinion, present a specific risk to the patient's safety.
        1. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
624 participants (estimated)

Study arms

  • Experimental
    Aumolertinib and platinum-based chemotherapy

    Drug: Aumolertinib

  • Active comparator
    Aumolertinib

    Drug: Placebo Aumolertinib

Interventions

  • Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles. Dose may be reduced to allow for the management of investigational drug related toxicity.

    Also known as: HS-10296

  • DrugPlacebo Aumolertinib

    Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.

06

What researchers measure

Primary outcomes

  1. PFS (Progression Free Survival) assessed by IRC (Independent Review Committee)

    IRC-PFS is defined as the time from randomization until the date of objective disease progression based on IRC assessment or death (by any cause in the absence of progression). The patients will receive long-term follow-up including chest and abdominal CT every 6 weeks until Week 18, then every 12 weeks and onwards.

    Time frame: From the time of randomization to disease progression or death, approximately 3 years.

Secondary outcomes

  1. ORR (Objective Response Rate) assessed by IRC (Independent Review Committee)

    ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression.

    Time frame: From the time of randomization to the date of first occurrence of complete response (CR) or partial response (PR), approximately 3 years.

  2. DoR (Duration of response)

    DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression.

    Time frame: From the time of randomization to disease progression or death, approximately 3 years.

  3. DCR (Disease Control Rate)

    The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD.

    Time frame: From the time of randomization to disease progression or death, approximately 3 years.

  4. DepOR (Depth of Response)

    DepOR is defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions.

    Time frame: From the time of randomization to disease progression or death, approximately 3 years.

  5. PFS (Progression Free Survival) Rate at 12, 18, 24, and 36 months

    PFS Rate at 12, 18, 24, and 36 months is defined as proportion of progression free survival at 12, 18, 24, and 36 months from the date of randomization.

    Time frame: The PFS Rate at 12, 18, 24, and 36 months is assessed up to 36 months.

  6. OS (Overall survival)

    Overall survival (OS) is defined as the time from randomization to death due to any cause. The survival will be followed up with telephone every 12 weeks after discontinuation of the randomized treatment.

    Time frame: From the time of randomization to death due to any cause, approximately 6 years.

  7. OS (Overall survival) rate at 3, 5 years

    OS rate at 3, 5 years is defined as the proportion of patients alive at 3, 5 years from the date of randomization.

    Time frame: The OS rate at 3, 5 years is assessed up to 5 years.

  8. Incidence and severity of AEs (Adverse Events)

    AEs are graded according to CTCAE v5.0 and recorded in the case report form.

    Time frame: From the screening period to 28 days after treatment completion, approximately 4 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jun 2024, 34 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2021
First posted
Jun 11, 2021
StartActual
Aug 11, 2021
Primary completionActual
Jun 18, 2024
CompletionEst.
Jan 31, 2026
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04923906
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Aug 11, 2021
Primary completion
Jun 18, 2024
Completion
Jan 31, 2026 (estimated)
Last update
Nov 25, 2024

Study contacts

Shun Lu, MD
principal investigator · Shanghai Chest Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion